How many years can a patient with diffuse B-cell lymphoma live?

Generally, “diffuse B-cell lymphoma” refers to diffuse large B-cell lymphoma (DLBCL). Patient survival varies considerably and is influenced by multiple factors. A detailed analysis follows:

For treatment-naïve patients with DLBCL, standard regimens—such as R-CHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone)—yield favorable outcomes in approximately 60–70% of cases, with a 5-year overall survival rate of about 50–60%.

However, prognosis may be relatively poor in patients who are older or present with multiple adverse prognostic factors—including poor performance status, extensive extranodal involvement, elevated serum lactate dehydrogenase (LDH) levels, or systemic “B symptoms” (e.g., fever, night sweats, and unintentional weight loss). In such cases, the 5-year survival rate may decline to 30–40% or even lower. Moreover, patients with relapsed or refractory DLBCL generally have an unfavorable prognosis; long-term survival remains low even after salvage therapy.

Overall survival in DLBCL is determined by a complex interplay of multiple factors, and clinical outcomes vary significantly among individuals. Patients should actively adhere to treatment, maintain a positive mindset, and adopt healthy lifestyle habits to optimize their prognosis.